Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
6 March 2007 | Volume 146 Issue 5 | Pages 317-325
Background: Anxiety, although as common as depression, has received less attention and is often undetected and undertreated.
Objective: To determine the current prevalence, impairment, and comorbidity of anxiety disorders in primary care and to evaluate a brief measure for detecting these disorders.
Design: Criterion-standard study performed between November 2004 and June 2005.
Setting: 15 U.S. primary care clinics.
Participants: 965 randomly sampled patients from consecutive clinic patients who completed a self-report questionnaire and agreed to a follow-up telephone interview.
Measurements: 7-item anxiety measure (Generalized Anxiety Disorder [GAD]-7 scale) in the clinic, followed by a telephone-administered, structured psychiatric interview by a mental health professional who was blinded to the GAD-7 results. Functional status (Medical Outcomes Study Short Form-20), depressive and somatic symptoms, and self-reported disability days and physician visits were also assessed.
Results: Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder, 6.8% (CI, 5.3% to 8.6%) had a panic disorder, and 6.2% (CI, 4.7% to 7.9%) had a social anxiety disorder. Each disorder was associated with substantial impairment that increased significantly (P < 0.001) as the number of anxiety disorders increased. Many patients (41%) with an anxiety disorder reported no current treatment. Receiver-operating characteristic curve analysis showed that both the GAD-7 scale and its 2 core items (GAD-2) performed well (area under the curve, 0.80 to 0.91) as screening tools for all 4 anxiety disorders.
Limitation: The study included a nonrandom sample of selected primary care practices.
Conclusions: Anxiety disorders are prevalent, disabling, and often untreated in primary care. A 2-item screening test may enhance detection.
Editors' Notes
Context
Contribution
Implications
The Editors
Author and Article Information
From Regenstrief Institute for Health Care and Indiana University, Indianapolis, Indiana; New York State Psychiatric Institute and Columbia University, New York, New York; and University of Heidelberg, Heidelberg, Germany.
Acknowledgments: The authors thank Monika Mussell, PhD, and Dieter Schellberg, PhD, University of Heidelberg, Heidelberg, Germany, for their invaluable assistance in some data analyses.
Grant Support: Pfizer Inc.
Potential Financial Conflicts of Interest: Consultancies: K. Kroenke (Eli Lilly Inc., Pfizer Inc.), J.B.W. Williams (Eli Lilly Inc., GlaxoSmithKline); Honoraria: K. Kroenke (Eli Lilly Inc., Wyeth); Grants received: K. Kroenke (Eli Lilly Inc., Pfizer Inc., Wyeth), R.L. Spitzer (Pfizer Inc.), J.B.W. Williams (Pfizer Inc.), B. Löwe (Pfizer Inc.).
Requests for Single Reprints: Kurt Kroenke, MD, Regenstrief Institute, 1050 Wishard Boulevard, Indianapolis, IN 46202; e-mail, kkroenke{at}regenstrief.org.
Current Author Addresses: Dr. Kroenke: Regenstrief Institute for Health Care, 1050 Wishard Boulevard, Indianapolis, IN 46202.
Drs. Spitzer and Williams: New York State Psychiatric Institute, Unit 60, 1051 Riverside Drive, New York, NY 10533.
Dr. Monahan: Division of Biostatistics, Department of Medicine, Indiana University, 1050 Wishard Boulevard, RG4 101, Indianapolis, IN 46202.
Dr. Löwe: Klinik für Psychosomatische und Allgemeine Klinische Medizin, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Author Contributions: Conception and design: K. Kroenke, R.L. Spitzer, J.B.W. Williams, B. Löwe.
Analysis and interpretation of the data: K. Kroenke, R.L. Spitzer, J.B.W. Williams, P.O. Monahan, B. Löwe.
Drafting of the article: K. Kroenke.
Critical revision of the article for important intellectual content: K. Kroenke, R.L. Spitzer, P.O. Monahan, B. Löwe.
Final approval of the article: K. Kroenke, R.L. Spitzer, J.B.W. Williams, P.O. Manahan, B. Löwe.
Statistical expertise: K. Kroenke, R.L. Spitzer, P.O. Monahan.
Obtaining of funding: K. Kroenke, R.L. Spitzer, B. Löwe.
Collection and assembly of data: J.B.W. Williams. ARTICLE
Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, and Detection
![]()
![]()
Related articles in Annals:
This article has been cited by other articles:
![]() |
D. Cukor, S. D. Cohen, R. A. Peterson, and P. L. Kimmel Psychosocial Aspects of Chronic Disease: ESRD as a Paradigmatic Illness J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3042 - 3055. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Skapinakis The 2-item Generalized Anxiety Disorder scale had high sensitivity and specificity for detecting GAD in primary care Evid. Based Med., October 1, 2007; 12(5): 149 - 149. [Full Text] [PDF] |
||||
![]() |
Anxiety Disorders Are Common and Undertreated in Primary Care Journal Watch (General), March 20, 2007; 2007(320): 2 - 2. [Full Text] |
||||
![]() |
W. Katon and P. Roy-Byrne Anxiety Disorders: Efficient Screening Is the First Step in Improving Outcomes Ann Intern Med, March 6, 2007; 146(5): 390 - 392. [Full Text] [PDF] |
||||
Read all Rapid Responses